View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 22, 2022

Galapagos to buy CellPoint, AboundBio to boost access to cell therapies

AboundBio will receive $14m from Galapagos under the agreed transaction.

Galapagos has signed agreements to acquire all outstanding shares of CellPoint and AboundBio to boost access to next-generation cell therapies, in an all-cash deal totalling $251m.

Under the definitive agreements signed between the companies, Galapagos will pay $132m (€125m) upfront to CellPoint while a milestone payment of an additional $105m (€100m) to be made is contingent on meeting certain goals.

In addition, AboundBio will receive $14m from Galapagos under the agreed transaction. 

Galapagos obtains access to a scalable, decentralised and automated point-of-care cell therapy supply model and a fully human antibody-based therapeutics platform with the takeover of CellPoint and AboundBio, respectively. 

These companies can potentially alter the chimeric antigen receptor T cell (CAR-T) treatment paradigm when combined and supported by Galapagos as a completely integrated biopharma.

The acquisitions will expand the portfolio and expertise of Galapagos.

In a strategic partnership with Lonza, CellPoint developed a new point-of-care supply model that provides the potential for seven-day delivery of CAR-T therapies.

Furthermore, the model does not need complicated logistics thereby addressing key limitations of existing CAR-T therapies. 

This platform comprises end-to-end xCellit workflow management and monitoring software of CellPoint and the Cocoon system of Lonza. 

The Cocoon system is an automated cell and gene therapy manufacturing platform.

Regulatory agencies in the Netherlands, Spain and Belgium have granted approval for clinical trials with CellPoint’s decentralised supply model.

Two Phase I/IIa trials of a CD19 CAR-T product candidate in relapsed/refractory Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia are underway with topline data anticipated in the first half of next year.

These trials will aid in quick clinical validation of the CAR-T point-of-care supply model. 

Subsequently, CellPoint’s platform for new CAR-Ts originating from AboundBio’s fully human antibody-based library and biological drug discovery and engineering expertise will be used to advance three differentiated, next-generation CAR-T candidates to the clinic over the coming three years.

Galapagos CEO Paul Stoffels said: “Our goal is to bring three differentiated, next-generation CAR-T candidates into the clinic over the next three years. 

“This is a first key step in our strategic transformation to accelerate and diversify our pipeline with the aim to create short- and long-term value through focused external growth.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology